Marker Therapeutics, Inc. filed a Form 8-K on November 19, 2026, disclosing that it was awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas to support its lead investigational MAR-T cell therapy, MT-601 (neldaleucel), in a planned Phase 2 study.

Key Highlights

  • Grant amount: Marker Therapeutics was awarded a $16.2 million Product Development Research grant from CPRIT.
  • Grant purpose: The funds are designated to support advancement of the company's lead investigational MAR-T cell therapy, MT-601 (neldaleucel).
  • Planned study: The grant will support the planned Phase 2 APOLLO study, according to the filing.
  • Announcement date: The company issued a press release announcing the award on November 19, 2026.
  • Signing officer: The filing was signed by Juan Vera, President and Chief Executive Officer.

Marker Therapeutics Discloses $16.2 Million CPRIT Award for MT-601 Phase 2 Development

Marker Therapeutics, Inc. (NASDAQ:MRKR), a Houston, Texas-based company, disclosed in an 8-K current report dated November 19, 2026, that it received a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas, commonly referred to as CPRIT. The filing was made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

According to the filing, the grant will be used "to support the advancement of the Company's lead investigational MAR-T cell therapy, MT-601 (neldaleucel), in the planned Phase 2 APOLLO study." The company characterizes MT-601 (neldaleucel) as its lead investigational therapy. The filing does not provide additional details regarding the timeline, enrollment criteria, or structure of the APOLLO study beyond identifying it as a planned Phase 2 study.

The disclosure was made under Item 8.01 (Other Information) of the Form 8-K. A press release dated November 19, 2026, announcing the award is attached as Exhibit 99.1 and incorporated by reference in the filing. The report was signed by Juan Vera, President and Chief Executive Officer of Marker Therapeutics, Inc. The company is incorporated in Delaware and lists its principal executive offices at 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas 77021.

What Was Disclosed

Marker Therapeutics filed an 8-K on November 19, 2026, reporting a $16.2 million CPRIT Product Development Research grant intended to fund the planned Phase 2 APOLLO study of its investigational MAR-T cell therapy MT-601 (neldaleucel).